The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Nrf2 signaling in coordinated activation of antioxidant gene expression
Jaiswal, A. K. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.074 · Cited by 1,254
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060
Huang, H.-C., Nguyen, T., & Pickett, C. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206911200 · Cited by 1,034
Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke–induced emphysema in mice
Rangasamy, T., Cho, C. Y., Thimmulappa, R. K., Zhen, L., Srisuma, S. S., Kensler, T. W., Yamamoto, M., Petrache, I., Tuder, R. M., & Biswal, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421146 · Cited by 991
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986 · cited 1×
“Two mechanisms responsible for this dissociation have been suggested: (1) reactive cysteines of Keap1 crosslink after electrophilic reaction, thereby hampering Keap1mediated proteasomal degradation of Nrf2 [11], and (2) phosphorylation of Nrf2 by PKC promotes its dissociation from Keap1 [12].”
BackgroundCullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
Cited by
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903
Transcriptional Regulation by Nrf2
Tonelli, C., Chio, I. I. C., & Tuveson, D. A. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7342 · Cited by 2,192
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395
The emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
Hayes, J. D., & McMahon, M. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 869
Stress-activated cap’n’collar transcription factors in aging and human disease
Sykiotis, G. P., & Bohmann, D. (2010) · Science Signaling · doi:10.1126/scisignal.3112re3 · Cited by 776
Nrf2, the Master Regulator of Anti-Oxidative Responses
Vomund, S., Schäfer, A., Parnham, M., Brüne, B., & Von Knethen, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122772 · Cited by 752
Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., & Hayes, J. D. (2013) · Oncogene · doi:10.1038/onc.2012.388 · Cited by 657
LAU, A., VILLENEUVE, N., SUN, Z., WONG, P., & ZHANG, D. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.003 · Cited by 645
The Dual Roles of NRF2 in Cancer
Menegon, S., Columbano, A., & Giordano, S. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.002 · Cited by 633
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
“Epigenetic changes due to promoter hypermethylation of three CpG sites ofKEAP1 have been described in lung tumors, resulting in consequent NRF2 activation that could be reversed by 5-aza-29-deoxycitydine treatment (Wang et al., 2008).”
BackgroundThe Complex Interplay between Antioxidants and ROS in Cancer
Harris, I. S., & DeNicola, G. M. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.03.002 · Cited by 626
The KEAP1–NRF2 System in Cancer
Taguchi, K., & Yamamoto, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00085 · Cited by 527
“Second, epigenetic silencing of the KEAP1 gene has also been found to cause KEAP1 downregulation and NRF2 upregulation (50).”
BackgroundModulating NRF2 in Disease: Timing Is Everything
Dodson, M., de la Vega, M. R., Cholanians, A. B., Schmidlin, C. J., Chapman, E., & Zhang, D. D. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021856 · Cited by 522
Nrf2/Keap1/ARE signaling: Towards specific regulation
Ulasov, A. V., Rosenkranz, A. A., Georgiev, G. P., & Sobolev, A. S. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120111 · Cited by 508
Nrf2: friend or foe for chemoprevention?
Kensler, T. W., & Wakabayashi, N. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp231 · Cited by 484
Oxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway
Holze, C., Michaudel, C., Mackowiak, C., Haas, D. A., Benda, C., Hubel, P., Pennemann, F. L., Schnepf, D., Wettmarshausen, J., Braun, M., et al. (2018) · Nature Immunology · doi:10.1038/s41590-017-0013-y · Cited by 452
The complexity of the Nrf2 pathway: beyond the antioxidant response
Huang, Y., Li, W., Su, Z.-Y., & Kong, A.-N. T. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.08.001 · Cited by 445
Solis, L. M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N. C., Moran, C. A., Corvalan, A. H., Biswal, S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 428
Ooi, A., Wong, J.-C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W. H., Tan, M.-H., Zhang, Z., Yang, X. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.024 · Cited by 401
Deshmukh, P., Unni, S., Krishnappa, G., & Padmanabhan, B. (2017) · Biophysical Reviews · doi:10.1007/s12551-016-0244-4 · Cited by 398
The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism
Mitsuishi, Y., Motohashi, H., & Yamamoto, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00200 · Cited by 392
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
Kim, Y. R., Oh, J. E., Kim, M. S., Kang, M. R., Park, S. W., Han, J. Y., Eom, H. S., Yoo, N. J., & Lee, S. H. (2010) · The Journal of Pathology · doi:10.1002/path.2653 · Cited by 358
Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., Kong, W., Truong, D., Martin, S., Chaudhuri, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0127 · Cited by 345
Arlt, A., Sebens, S., Krebs, S., Geismann, C., Grossmann, M., Kruse, M.-L., Schreiber, S., & Schäfer, H. (2013) · Oncogene · doi:10.1038/onc.2012.493 · Cited by 330
Molecular Basis of Electrophilic and Oxidative Defense: Promises and Perils of Nrf2
Ma, Q., & He, X. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.004333 · Cited by 317
Targeting NRF2 signaling for cancer chemoprevention
Kwak, M.-K., & Kensler, T. W. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.08.028 · Cited by 305
Molecular Basis of the KEAP1-NRF2 Signaling Pathway
Suzuki, T., Takahashi, J., & Yamamoto, M. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.0028 · Cited by 301
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer
Adinolfi, S., Patinen, T., Jawahar Deen, A., Pitkänen, S., Härkönen, J., Kansanen, E., Küblbeck, J., & Levonen, A.-L. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102726 · Cited by 292
Beyond repression of Nrf2: An update on Keap1
Kopacz, A., Kloska, D., Forman, H. J., Jozkowicz, A., & Grochot-Przeczek, A. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.03.023 · Cited by 265
Epigenetic regulation of Keap1-Nrf2 signaling
Guo, Y., Yu, S., Zhang, C., & Kong, A.-N. T. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.013 · Cited by 258
The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment
Taguchi, K., & Yamamoto, M. (2020) · Cancers · doi:10.3390/cancers13010046 · Cited by 195
“In addition to these mutations, oncometabolites [70,71], exon skipping [72], and promoter methylation [73] lead to constitutive NRF2 activation in cancers [14,74].”
BackgroundKEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma
Li, Q. K., Singh, A., Biswal, S., Askin, F., & Gabrielson, E. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2010.172 · Cited by 90
Tao, J., Krutsenko, Y., Moghe, A., Singh, S., Poddar, M., Bell, A., Oertel, M., Singhi, A. D., Geller, D., Chen, X., et al. (2021) · Hepatology · doi:10.1002/hep.31730 · Cited by 54
Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
DeBlasi, J. M., Falzone, A., Caldwell, S., Prieto-Farigua, N., Prigge, J. R., Schmidt, E. E., Chio, I. I. C., Karreth, F. A., & DeNicola, G. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3848 · Cited by 49
“NRF2 stabilization is 53 associated with poor prognosis (13-20), resistance to chemo- and radiotherapy (21, 22), cancer cell 54 survival (22), proliferation (23), metabolic reprogramming (20, 24-26), and metastasis (27).”
Kari, E., Teppo, H.-R., Haapasaari, K.-M., Kuusisto, M. E. L., Lemma, A., Karihtala, P., Pirinen, R., Soini, Y., Jantunen, E., Turpeenniemi-Hujanen, T., et al. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205584 · Cited by 16
The complex role of NRF2 in cancer: A genomic view
Praslicka, B. J., Kerins, M. J., & Ooi, A. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.09.003 · Cited by 14
Utility of Checklist to Describe Experimental Methods for Investigating Molecular Biomarkers
Chiarella, P., Carbonari, D., & Iavicoli, S. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.82 · Cited by 5
Metadata
- Authors
- Wang, R., An, J., Ji, F., Jiao, H., Sun, H., & Zhou, D.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 373
- Issue
- 1
- Pages
- 151-154
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2116142441
- Cited by
- 259
- References
- 22
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.